Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Expert Rev Vaccines. 2010;9(3s):21-26. While there is still no standard definition for PHN, for the purposes of this review it is defined as: clinically significant pain or painful abnormal ...

The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

HSV and varicella zoster virus (VZV) are common pathogens ... [5] Despite the self-limiting characteristics of most herpes infections, growing public attention has been focused on these viruses ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

No new safety concerns and consistent safety profiles were observed for long-term risankizumab use in patients with psoriasis and PsA.

Announcing a new article publication for Zoonoses journal. The aim of this study was to monitor the spectrum of viral pathogens involved in febrile rash illness (FRI) and their epidemiology.

DAYBREAK was a Phase 3, multi-center, long-term open-label extension study to evaluate the safety and efficacy of Zeposia (ozanimod) administered orally to patients with relapsing forms of multiple ...

A total of 14,168 patients of all age groups were enrolled and tested for seven common viruses causing FRI: measles virus (MV), rubella virus (RuV), enterovirus (EV), varicella zoster virus (VZV), ...